Table 1 Cell cycle distribution of iPS cells treated with thymidine

MIFF1

 Sub-G1 phase

10.7 ± 2.2

18.5 ± 6.1

25.8 ± 12.5

38.5 ± 4.2**

51.1 ± 3.9***

 G1 phase

33.2 ± 3.4

44.5 ± 0.6*

38.3 ± 4.2

24.5 ± 5.1

20.3 ± 1.5*

 S phase

28.9 ± 1.4

20.2 ± 2.3*

23.7 ± 1.8

29.1 ± 4.8

18.7 ± 4.3*

 G2 phase

25.6 ± 2.2

15.7 ± 4.4*

10.6 ± 8.1*

7.4 ± 2.9**

8.7 ± 1.6**

 Total

98.3 ± 1.4

99.0 ± 1.5

98.4 ± 0.7

99.5 ± 1.4

98.9 ± 0.6

MIFF3

 Sub-G1 phase

11.4 ± 3.5

14.0 ± 5.9

26.7 ± 2.2*

34.4 ± 6.2*

44.5 ± 16.6*

 G1 phase

30.3 ± 2.3

41.4 ± 3.8*

31.0 ± 4.3

22.4 ± 1.7

21.0 ± 5.0*

 S phase

29.2 ± 0.8

29.1 ± 3.7

30.9 ± 3.1

30.9 ± 2.8

22.5 ± 4.8

 G2 phase

27.3 ± 5.0

14.7 ± 0.3*

10.7 ± 1.7*

11.2 ± 4.5*

11.0 ± 8.8*

 Total

98.2 ± 0.2

99.2 ± 1.4

99.2 ± 0.6

98.9 ± 0.5

98.9 ± 0.2

MIFF4

 Sub-G1 phase

9.7 ± 2.4

16.9 ± 5.9

22.1 ± 1.1*

25.2 ± 1.2*

36.8 ± 8.6*

 G1 phase

40.2 ± 8.1

40.1 ± 4.2

38.4 ± 4.5

31.3 ± 6.9

27.0 ± 3.6

 S phase

25.7 ± 2.5

26.1 ± 5.6

28.6 ± 2.6

31.4 ± 2.4

22.9 ± 5.7

 G2 phase

22.3 ± 7.6

15.0 ± 4.0

9.1 ± 1.2

10.5 ± 5.8

11.9 ± 6.3

 Total

97.8 ± 0.4

98.0 ± 0.5

98.1 ± 0.4

98.3 ± 0.1

98.5 ± 0.2